Your browser doesn't support javascript.
loading
Argentine consensus recommendations for lung cancer screening programmes: a RAND/UCLA-modified Delphi study.
Boyeras, Iris; Roberti, Javier; Seijo, Mariana; Suárez, Verónica; Morero, José Luis; Patané, Ana Karina; Kaen, Diego; Lamot, Sebastián; Castro, Mónica; Re, Ricardo; García, Artemio; Vujacich, Patricia; Videla, Alejandro; Recondo, Gonzalo; Fernández-Pazos, Alfonso; Lyons, Gustavo; Paladini, Hugo; Benítez, Sergio; Martín, Claudio; Defranchi, Sebastián; Paganini, Lisandro; Quadrelli, Silvia; Rossini, Sebastián; Garcia Elorrio, Ezequiel; Sobrino, Edgardo.
Afiliação
  • Boyeras I; Angel Roffo Oncology Institute, Universtiy of Buenos Aires, Buenos Aires, Argentina.
  • Roberti J; Department of Healthcare Quality and Patient Safety, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina jroberti@iecs.org.ar.
  • Seijo M; Centre for Research in Epidemiology and Public Health (CIESP), CONICET, Buenos Aires, Buenos Aires, Argentina.
  • Suárez V; Department of Healthcare Quality and Patient Safety, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
  • Morero JL; Pneumonology Service, Clínica Bazterrica, Buenos Aires, Argentina.
  • Patané AK; Alexander Fleming Institute, Buenos Aires, Argentina.
  • Kaen D; Municipal Hospital María Ferrer, Buenos Aires, Argentina.
  • Lamot S; Hospital de Clínicas Virgen María de Fátima, National University of La Rioja, La Rioja, Argentina.
  • Castro M; Conciencia Clinic, Neuquén, Argentina.
  • Re R; Angel Roffo Oncology Institute, Universtiy of Buenos Aires, Buenos Aires, Argentina.
  • García A; Center for Medical Education and Clinical Research Norberto Quirno (CEMIC), Buenos Aires, Argentina.
  • Vujacich P; Prof. Posadas National Hospital, El Palomar, Buenos Aires, Argentina.
  • Videla A; British Hospital of Buenos Aires, Buenos Aires, Federal District, Argentina.
  • Recondo G; Hospital de Clínicas José de San Martín, University of Buenos Aires, Buenos Aires, Argentina.
  • Fernández-Pazos A; Austral University Hospital, Pilar, Argentina.
  • Lyons G; Center for Medical Education and Clinical Research Norberto Quirno (CEMIC), Buenos Aires, Argentina.
  • Paladini H; OSDE, Buenos Aires, Argentina.
  • Benítez S; British Hospital of Buenos Aires, Buenos Aires, Federal District, Argentina.
  • Martín C; Medical Images Service MIT Group, Santa Fe, Argentina.
  • Defranchi S; Hospital Zonal Juan Ramón Carrillo, San Carlos de Bariloche, Río Negro, Argentina.
  • Paganini L; Alexander Fleming Institute, Buenos Aires, Argentina.
  • Quadrelli S; Municipal Hospital María Ferrer, Buenos Aires, Argentina.
  • Rossini S; Favaloro Foundation University Hospital, Buenos Aires, Federal District, Argentina.
  • Garcia Elorrio E; Alexander Fleming Institute, Buenos Aires, Argentina.
  • Sobrino E; British Hospital of Buenos Aires, Buenos Aires, Federal District, Argentina.
BMJ Open ; 13(2): e068271, 2023 02 03.
Article em En | MEDLINE | ID: mdl-36737082
BACKGROUND: Lung cancer (LC) screening improves LC survival; the best screening method in terms of improving survival is low-dose CT (LDCT), outpacing chest X-ray and sputum cytology. METHODS: A consensus of experts in Argentina was carried out to review the literature and generate recommendations for LC screening programmes. A mixed-method study was used with three phases: (1) review of the literature; (2) modified Delphi consensus panel; and (3) development of the recommendations. The Evidence to Decision (EtD) framework was used to generate 13 evaluation criteria. Nineteen experts participated in four voting rounds. Consensus among participants was defined using the RAND/UCLA method. RESULTS: A total of 16 recommendations scored ≥7 points with no disagreement on any criteria. Screening for LC should be performed with LDCT annually in the population at high-risk, aged between 55 and 74 years, regardless of sex, without comorbidities with a risk of death higher than the risk of death from LC, smoking ≥30 pack-years or former smokers who quit smoking within 15 years. Screening will be considered positive when finding a solid nodule ≥6 mm in diameter (or ≥113 mm3) on baseline LDCT and 4 mm in diameter if a new nodule is identified on annual screening. A smoking cessation programme should be offered, and cardiovascular risk assessment should be performed. Institutions should have a multidisciplinary committee, have protocols for the management of symptomatic patients not included in the programme and distribute educational material. CONCLUSION: The recommendations provide a basis for minimum requirements from which local institutions can develop their own protocols adapted to their needs and resources.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Humans / Middle aged País/Região como assunto: America do sul / Argentina Idioma: En Revista: BMJ Open Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Argentina

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Humans / Middle aged País/Região como assunto: America do sul / Argentina Idioma: En Revista: BMJ Open Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Argentina